[1] Fukui H,Saito H,Ueno Y,et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol,2016, 51（7）:629-650.
[2] Eom YW,Kim G,Baik SK. Mesenchymal stem cell therapy for cirrhosis:Present and future perspectives. World J Gastroenterol,2015,21（36）:10253-10261.
[3] Lukashyk SP,Tsyrkunov VM,Isaykina YI,et al. Mesenchymal bone marrow-derived stem cells transplantation in patients with HCV related liver cirrhosis. J Clin Transl Hepatol,2014,2（4）:217-221.
[4] 何刚,李宏波,肝炎后肝硬化血象及骨髓象的临床分析. 全科医学临床与教育,2014,14（2）:188.
[5] 陆光生,景晔,徐和福,等. 肝炎肝硬化患者血常规和骨髓祖细胞造血功能的改变. 解放军预防医学杂志,2013,23（5）:421-424.
[6] 陆光生,景晔,徐和福,等. 肝炎肝硬化血细胞减少与骨髓病态造血及脾功能相关性研究. 中国医学装备,2016,16（11）:93-97.
[7] 杨日东.失代偿期肝硬化患者骨髓细胞学检查结果分析. 包头医学院学报,2016,32（1）:42-43.
[8] Gangireddy VG,Kanneganti PC,Sridhar S,et al. Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol,2014,28（10）:558-564.
[9] Witters P,Freson K,Verslype C,et al. Review article:blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther,2008,27（11）:1017-1029.
[10] Mirshekar-Syahkal B,Fitch SR,Ottersbach K. From greenhouse to garden:the changing soil of the hematopoietic stem cell microenvironment during development. Stem Cells,2014,32（7）:1691-1700.
[11] Bihari C,Anand L,Rooge S,et al. Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver. Hepatology,2016,64（4）:1273-1288.
[12] Mendelson A,Frenette PS,Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med,2014,20（8）:833-846.
[13] Arranz L,Sanchez-Aguilera A,Martin-Perez D,et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature,2014,512（7512）:78-81.
[14] Perrotta S,Cucciolla V,Ferraro M,et al. EPO receptor gain-of-function causes hereditary polycythemia,alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One,2010,5（8）:e12015.
[15] Yang YY,Lin HC,Lee WC,et al. Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. J Gastroenterol Hepatol,2003,18（10）:1156-1161.
[16] Kubota A,Okamura S,Omori F,et al. High serum levels of granulocyte-macrophage colony-stimulating factor in patients with liver cirrhosis and granulocytopenia. Clin Lab Haematol,1995,17（1）:61-63.
[17] Chou FS,Mulloy JC. The thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis. J Cell Biochem,2011,112（6）:1491-1498.
[18] Peck-Radosavljevic M,Zacherl J,Meng YG,et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver. J Hepatol,1997,27（1）:127-131.
[19] 王顺达,党双锁,程延安,等. 肝炎肝硬化患者骨髓TPO、GM-CSF表达与外周血细胞的关系. 西安交通大学学报-医学版,2010,32（5）:531-553.
[20] Lefrancais E,Ortiz-Munoz G,Caudrillier A,et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature,2017,544（7648）:105-109. |
